指南与共识支持与姑息治疗

NCCN指南超出FDA批准适应证的推荐证据强度再分析

Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals.
指南 / 共识 · Ann Oncol · 2019-01-01

该研究对先前分析中列出的44条NCCN超说明书推荐进行深入再分析,评估其证据强度。结果显示,14条后来获FDA批准或有大样本随机对照试验数据支持,13条为轻微外推或实为说明书内推荐;剩余17条中8条为罕见肿瘤中机制性药物(中位缓解率43%),7条基于非随机对照试验数据(缓解率>50%),2条因新疗法出现而被移除。结论认为NCCN超说明书推荐的证据强度总体稳健。

要点

  • 44条NCCN超说明书推荐中,14条后来获FDA批准或获RCT数据支持。
  • 13条为轻微外推或实为说明书内推荐,仅17条为真正外推。
  • 剩余17条中多数基于机制性药物高缓解率或非随机对照试验显著疗效。

核心结论

  • NCCN超说明书推荐中相当比例随后获得FDA批准或RCT支持,证据强度总体稳健。

研究设计与样本

  • 对先前分析中44条NCCN超说明书推荐进行深入再分析的描述性研究。

主要发现

  • 44条超说明书推荐中,14条后来获FDA批准和/或获RCT数据支持。
  • 13条推荐为轻微外推(n=8)或实为说明书内推荐(n=5)。
  • 剩余17条外推中,8条为罕见肿瘤或治疗选择少的亚组中机制性药物(中位缓解率43%)。
  • 7条基于非随机对照试验数据显示显著疗效(缓解率>50%)。
  • 2条因更新疗法具有更好活性或安全性而被从NCCN指南中移除。

临床怎么用

  • 临床医生可参考NCCN超说明书推荐,但需注意其证据来源多为机制性药物在罕见肿瘤中的高缓解率或非随机对照试验数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A previous analysis of 113 National Comprehensive Cancer Network® (NCCN®) recommendations reported that NCCN frequently recommends beyond Food and Drug Administration (FDA)-approved indications (44 off-label recommendations) and claimed that the evidence for these recommendations was weak. METHODS: In order to determine the strength of the evidence, we carried out an in-depth re-analysis of the 44 off-label recommendations listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). RESULTS: Of the 44 off-label recommendations, 14 were later approved by the FDA and/or are supported by randomized controlled trial (RCT) data. In addition, 13 recommendations were either very minor extrapolations from the FDA label (n = 8) or were actually on-label (n = 5). Of the 17 remaining extrapolations, 8 were for mechanism-based agents applied in rare cancers or subsets with few available treatment options (median response rate = 43%), 7 were based on non-RCT data showing significant efficacy (>50% response rates), and 2 were later removed from the NCCN Guidelines because newer therapies with better activity and/or safety became available. CONCLUSION: Off-label drug use is a frequent component of care for patients with cancer in the United States. Our findings indicate that when the NCCN recommends beyond the FDA-approved indications, the strength of the evidence supporting such recommendations is robust, with a significant subset of these drugs later becoming FDA approved or supported by RCT. Recommendations without RCT data are often for mechanism-based drugs with high response rates in rare cancers or subsets without effective therapies.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Kurzrock R, Gurski LA, Carlson RW, et al. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. Ann Oncol. 2019. PMID: 31373348. doi:10.1093/annonc/mdz232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。